• PDF: Delivered by email usually within 12 to 48 UK business hours.

Emerging Cancer Vaccines Market to 2017
Novel, First-in-Class Vaccines in Phase Ii and Phase Iii Pipeline to Shape The Future Cancer Vaccines Market

  • Publication Date:October 2011
  • Publisher:GBI Research
  • Product Type: Report
  • Pages:154

Emerging Cancer Vaccines Market to 2017 Novel, First-in-Class Vaccines in Phase Ii and Phase Iii Pipeline to Shape The Future Cancer Vaccines Market

Emerging Cancer Vaccines Market to 2017 - Novel, First-In-Class Vaccines in Phase II and Phase III Pipeline to Shape the Future Cancer Vaccines Market

Summary

GBI Research, the leading business intelligence provider, has released its latest research, "Emerging Cancer Vaccines Market to 2017 - Novel, First-In-Class Vaccines in Phase II and Phase III Pipeline to Shape the Future Cancer Vaccines Market", which provides insights into the global emerging cancer vaccines market and a market forecast until 2017. The report provides an in-depth analysis of the five therapeutic indications for which vaccines are available in the market or which have a promising vaccine in Phase III of their pipeline. In addition, the report also includes various types of cancer vaccine development and vaccine delivery methods along with a case study, advantages and disadvantages for each type, insights into the cancer vaccines R&D pipeline, SWOT profiles of the vaccine companies, and major Mergers and Acquisitions (M&A), deals and co-developments.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

GBI Research's analysis shows that the global cancer vaccines market for cervical cancer, prostate cancer, lung cancer, pancreatic cancer and melanoma was valued at $1,657m in 2010. The market is expected to witness a Compound Annual Growth Rate (CAGR) of 21% for the forecast period (2010-2017) and will reach $6.3 billion by 2017. The market will be driven by the launch of promising Phase III molecules in cervical cancer, lung cancer, pancreatic cancer and melanoma. With patent-protection granted to available vaccines, the market will demonstrate significant growth. Strategic consolidations through M&A, deals and co-developments will provide R&D, marketing, sales and regulatory support in the future and help gain a greater market share.

Scope

  • The report provides a market characterization, pipeline analysis and key M&A trends in the cervical cancer, prostate cancer, lung cancer, pancreatic cancer and melanoma vaccines market.
  • Descriptive case studies, advantages and disadvantages for various types of cancer vaccine development and vaccine delivery methods
  • Data and analysis on the emerging cancer vaccines market
  • Annualized market data for the cancer vaccines market, with forecasts to 2017
  • Market data on the therapeutic landscape which covers cervical cancer, prostate cancer, lung cancer, pancreatic cancer and melanoma, including market size, market share and annual cost of vaccination
  • Key drivers and restraints that have had a significant impact on the market and on each indication
  • The competitive landscape of the emerging cancer vaccines market which includes companies such as Merck, Amgen, GlaxoSmithKline, Dendreon
  • Key M&A, deals and co-developments that took place from 2004 to 2011 in the global cancer vaccines market

Reasons to buy

The report will enhance your decision-making capability. It will allow you to -

  • Familiarize yourself with the different types of cancer vaccine development and vaccine delivery methods available, with case studies and analysis of advantages and disadvantages for a better understanding of the market.
  • Align your product portfolio to the markets with high growth potential.
  • Develop market-entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.
  • Devise a more tailored country strategy through the understanding of key drivers and barriers of each region's cancer vaccines market.
  • Develop key strategic initiatives by understanding the key focus areas and top selling vaccines of leading companies.
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.
  • 1 Table of Contents
    • 1.1 List of Tables
    • 1.2 List of Figures
  • 2 Emerging Cancer Vaccines Market to 2017: Introduction
    • 2.1 GBI Research Report Guidance
  • 3 Emerging Cancer Vaccines Market to 2017: Cancer Vaccine Development
    • 3.1 Different Approaches to Cancer Vaccine Development
    • 3.1.1 Whole-Cell Cancer Vaccines
    • 3.1.2 Antigen Vaccines
    • 3.1.3 DNA Vaccines
    • 3.1.4 Vector-based Vaccines
    • 3.1.5 Dendritic Cell (DC) Vaccines
    • 3.1.6 Idiotype Vaccines
    • 3.2 Cancer Vaccines in Combination Therapy (Adjuvants)
    • 3.2.1 Microbes
    • 3.2.2 Substances Produced by Bacteria
    • 3.2.3 Biological Products Derived from Non-Microbial Organisms
    • 3.2.4 Non-Biological Substances
    • 3.2.5 Natural or Synthetic Cytokines
  • 4 Emerging Cancer Vaccines Market to 2017: Physical Delivery Methods
    • 4.1 Introduction
    • 4.1.1 Tattooing
    • 4.1.2 Gene Gun
    • 4.1.3 Ultrasound
    • 4.1.4 Electroporation
    • 4.1.5 Laser
  • 5 Emerging Cancer Vaccines Market to 2017: Non-Physical Delivery Methods
    • 5.1 Biological Gene Delivery Systems (Viral Vectors)
    • 5.2 Non-Biological Gene Delivery Systems (Non-Viral Vectors)
    • 5.2.1 Cationic Lipids/Liposomes
    • 5.2.2 Polysaccharides and Cationic Polymers
    • 5.2.3 Micro/Nano-particles
    • 5.2.4 Cationic Peptides/CPP
    • 5.2.5 Virus-Like Particles (VLPs) as an Efficient Delivery System
    • 5.2.6 Delivery Systems in DC Vaccines
    • 5.2.7 Delivery Systems in Protein/Peptide Vaccines
    • 5.2.8 Mucosal Delivery System
  • 6 Emerging Cancer Vaccines Market to 2017: Market Overview
    • 6.1 Introduction
    • 6.2 Revenue
    • 6.3 Annual Cost of Vaccination
    • 6.4 Target Population
    • 6.4.1 Coverage Population
    • 6.5 Unmet Needs
    • 6.6 Drivers and Restraints
    • 6.6.1 Drivers
    • 6.6.2 Restraints
  • 7 Emerging Cancer Vaccines Market to 2017: Therapeutic Landscape
    • 7.1 Cervical Cancer Vaccines Market
    • 7.1.1 Introduction
    • 7.1.2 Unmet Needs
    • 7.1.3 Revenue
    • 7.1.4 Annual Cost of Vaccination
    • 7.1.5 Target Population
    • 7.1.6 Geographical Segmentation
    • 7.1.7 Drivers and Restraints for the Cervical Cancer Vaccines Market
    • 7.2 Prostate Cancer Vaccine Market
    • 7.2.1 Introduction
    • 7.2.2 Unmet Needs
    • 7.2.3 Revenue
    • 7.2.4 Annual Cost of Vaccination
    • 7.2.5 Target Population
    • 7.2.6 Geographical Segmentation
    • 7.2.7 Drivers and Restraints for the Prostate Cancer Vaccines Market
    • 7.3 Lung Cancer Vaccines Market
    • 7.3.1 Introduction
    • 7.3.2 Unmet Needs
    • 7.3.3 Revenue
    • 7.3.4 Annual Cost of Vaccination
    • 7.3.5 Target Population
    • 7.3.6 Geographical Segmentation
    • 7.3.7 Drivers and Restraints for the Lung Cancer Vaccines Market
    • 7.4 Pancreatic Cancer Vaccines Market
    • 7.4.1 Introduction
    • 7.4.2 Unmet Needs
    • 7.4.3 Revenue
    • 7.4.4 Annual Cost of Vaccination
    • 7.4.5 Target Population
    • 7.4.6 Geographical Segmentation
    • 7.4.7 Drivers and Restraints for the Pancreatic Cancer Vaccines Market
    • 7.5 Melanoma Vaccines Market
    • 7.5.1 Introduction
    • 7.5.2 Unmet Needs
    • 7.5.3 Revenue
    • 7.5.4 Annual Cost of Vaccination
    • 7.5.5 Target Population
    • 7.5.6 Geographical Segmentation
    • 7.5.7 Drivers and Restraints for the Melanoma Vaccines Market
  • 8 Emerging Cancer Vaccines Market to 2017: Geographical Landscape
    • 8.1 The US
    • 8.1.1 Revenue
    • 8.1.2 Annual Cost of Vaccination
    • 8.1.3 Target Population
    • 8.2 Top Five Countries in Europe
    • 8.2.1 Revenue
    • 8.2.2 Annual Cost of Vaccination
    • 8.2.3 Target Population
    • 8.3 Japan
    • 8.3.1 Revenue
    • 8.3.2 Annual Cost of Vaccination
    • 8.3.3 Target Population
  • 9 Emerging Cancer Vaccines Market to 2017: Pipeline Analysis
    • 9.1 Introduction
    • 9.1.1 Research and Development Pipeline - Prostate Cancer Vaccines
    • 9.1.2 Research and Development Pipeline - Lung Cancer Vaccines
    • 9.1.3 Research and Development Pipeline - Pancreatic Cancer Vaccines
    • 9.1.4 Research and Development Pipeline - Melanoma Vaccines
    • 9.1.5 Research and Development Pipeline - Cervical Cancer Vaccines
    • 9.2 R&D Trends
    • 9.3 Profiles of Promising Drugs in the Emerging Cancer Vaccines Market to 2017
    • 9.3.1 Stimuvax
    • 9.3.2 OncoVEXGM-CSF
    • 9.3.3 V503
    • 9.3.4 GV1001
    • 9.3.5 Lucanix
    • 9.3.6 TG4010
  • 10 Emerging Cancer Vaccines Market to 2017: Competitive Landscape
    • 10.1 Marketed Cancer Vaccines
    • 10.1.1 Gardasil
    • 10.1.2 Cervarix
    • 10.1.3 Provenge
    • 10.2 Market Share Analysis
    • 10.3 Competitive Profiling
    • 10.3.1 Merck & Co., Inc
    • 10.3.2 Merck Serono
    • 10.3.3 Amgen
    • 10.3.4 GlaxoSmithKline
    • 10.3.5 Dendreon
    • 10.3.6 KAEL-Gemvax
  • 11 Emerging Cancer Vaccines Market to 2017: Strategic Consolidations
    • 11.1 Overview
    • 11.1.1 M&A by Year
    • 11.1.2 M&A by Geography
    • 11.1.3 M&A by Value
    • 11.1.4 M&A by Type
    • 11.1.5 M&A by Company
    • 11.1.6 Top 10 M&A
    • 11.2 R&D Licensing Agreements
    • 11.2.1 Deals by Year
    • 11.2.2 Deals by Geography
    • 11.2.3 Deals by Value
    • 11.2.4 Deals by Company
    • 11.2.5 Top 10 Deals
    • 11.3 Co-Developments
    • 11.3.1 Co-Developments by Year
    • 11.3.2 Co-Developments by Geography
    • 11.3.3 Co-Developments by Value
    • 11.3.4 Top Five Co-Developments
  • 12 Emerging Cancer Vaccines Market to 2017: Appendix
    • 12.1 Market Definitions
    • 12.2 Abbreviations
    • 12.3 Research Methodology
    • 12.3.1 Cancer Vaccine Development
    • 12.3.2 Vaccine Delivery Methods
    • 12.3.3 Market Overview
    • 12.3.4 Therapeutic Landscape
    • 12.3.5 Geographical Landscape
    • 12.3.6 Pipeline Analysis
    • 12.3.7 Competitive Landscape
    • 12.3.8 Strategic Consolidations
    • 12.4 Contact Us
    • 12.5 Disclaimer
    • 12.6 Sources
  • 1.1 List of Tables
    • Table 1: Emerging Cancer Vaccines Market, Global, Revenue ($m), 2006-2010
    • Table 2: Emerging Cancer Vaccines Market, Global, Revenue Forecasts ($m), 2010-2017
    • Table 3: Emerging Cancer Vaccines Market, Global, Annual Cost of Vaccination ($), 2006-2010
    • Table 4: Emerging Cancer Vaccines Market, Global, Annual Cost of Vaccination ($), 2010-2017
    • Table 5: Emerging Cancer Vaccines Market, Global, Target and Coverage Population ('000), 2006-2010
    • Table 6: Emerging Cancer Vaccines Market, Global, Target and Coverage Population ('000), 2010-2017
    • Table 7: Cervical Cancer Vaccines Market, Global, Revenue ($m), 2006-2010
    • Table 8: Cervical Cancer Vaccines Market, Global, Revenue Forecasts ($m), 2010-2017
    • Table 9: Cervical Cancer Vaccines Market, Global, Annual Cost of Vaccination ($), 2006-2010
    • Table 10: Cervical Cancer Vaccines Market, Global, Annual Cost of Vaccination ($), 2010-2017
    • Table 11: Cervical Cancer Vaccines Market, Global, Target and Coverage Population ('000), 2006-2010
    • Table 12: Cervical Cancer Vaccines Market, Global, Target and Coverage Population ('000), 2010-2017
    • Table 13: Cervical Cancer Vaccines Market, Geographical Segmentation, Revenue ($m), 2006-2010
    • Table 14: Cervical Cancer Vaccines Market, Geographical Segmentation, Revenue Forecasts ($m), 2010-2017
    • Table 15: Prostate Cancer Vaccines Market, Global, Revenue Forecasts ($m), 2010-2017
    • Table 16: Prostate Cancer Vaccines Market, Global, Annual Cost of Vaccination ($), 2010-2017
    • Table 17: Prostate Cancer Vaccines Market, Global, Target and Coverage Population ('000), 2010-2017
    • Table 18: Prostate Cancer Vaccines Market, Geographical Segmentation, Revenue Forecasts ($m), 2010-2017
    • Table 19: Lung Cancer Vaccines Market, Global, Revenue Forecasts ($m), 2010-2017
    • Table 20: Lung Cancer Vaccines Market, Global, Annual Cost of Vaccination ($), 2010-2017
    • Table 21: Lung Cancer Vaccines Market, Global, Target and Coverage Population ('000), 2010-2017
    • Table 22: Lung Cancer Vaccines Market, Geographical Segmentation, Revenue Forecasts ($m), 2010-2017
    • Table 23: Pancreatic Cancer Vaccines Market, Global, Revenue Forecasts ($m), 2010-2017
    • Table 24: Pancreatic Cancer Vaccines Market, Global, Annual Cost of Vaccination ($), 2010-2017
    • Table 25: Pancreatic Cancer Vaccines Market, Global, Target and Coverage Population ('000), 2010-2017
    • Table 26: Pancreatic Cancer Vaccines Market, Global, Geographical Segmentation, Revenue Forecasts ($m), 2010-2017
    • Table 27: Melanoma Vaccines Market, Global, Revenue Forecasts ($m), 2010-2017
    • Table 28: Melanoma Vaccines Market, Global, Annual Cost of Vaccination ($), 2010-2017
    • Table 29: Melanoma Cancer Vaccines Market, Global, Target and Coverage Population ('000), 2010-2017
    • Table 30: Melanoma Vaccines Market, Global, Geographical Segmentation, Revenue Forecasts ($m), 2010-2017
    • Table 31: Emerging Cancer Vaccines Market, The US, Revenue ($m), 2006-2010
    • Table 32: Emerging Cancer Vaccines Market, The US, Revenue Forecasts ($m), 2010-2017
    • Table 33: Emerging Cancer Vaccines Market, The US, Annual Cost of Vaccination ($), 2006-2010
    • Table 34: Emerging Cancer Vaccines Market, The US, Annual Cost of Vaccination ($), 2010-2017
    • Table 35: Emerging Cancer Vaccines Market, The US, Target and Coverage Population ('000), 2006-2010
    • Table 36: Emerging Cancer Vaccines Market, The US, Target and Coverage Population ('000), 2010-2017
    • Table 37: Emerging Cancer Vaccines Market, Top Five Countries of Europe, Revenue ($m), 2006-2010
    • Table 38: Emerging Cancer Vaccines Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2010-2017
    • Table 39: Emerging Cancer Vaccines Market, Top Five Countries of Europe, Annual Cost of Vaccination ($), 2006-2010
    • Table 40: Emerging Cancer Vaccines Market, Top Five Countries of Europe, Annual Cost of Vaccination ($), 2010-2017
    • Table 41: Emerging Cancer Vaccines Market, Top Five Countries of Europe, Target and Coverage Population ('000), 2006-2010
    • Table 42: Emerging Cancer Vaccines Market, Top Five Countries of Europe, Target and Coverage Population ('000), 2010-2017
    • Table 43: Emerging Cancer Vaccines Market, Japan, Revenue Forecasts ($m), 2010-2017
    • Table 44: Emerging Cancer Vaccines Market, Japan, Annual Cost of Vaccination ($), 2010-2017
    • Table 45: Emerging Cancer Vaccines Market, Japan, Target and Coverage Population ('000), 2010-2017
    • Table 46: Prostate Cancer Vaccines Market, Global, Pipeline Analysis, 2011
    • Table 47: Lung Cancer Vaccines Market, Global, Pipeline Analysis, 2011
    • Table 48: Pancreatic Cancer Vaccines Market, Global, Pipeline Analysis, 2011
    • Table 49: Melanoma Vaccines Market, Global, Pipeline Analysis, 2011
    • Table 50: Cervical Cancer Vaccines Market, Global, Pipeline Analysis, 2011
    • Table 51: Emerging Cancer Vaccines Market, Global, Pipeline Products, Merck & Co., Inc., 2011
    • Table 52: Emerging Cancer Vaccines Market, Global, Pipeline Products, Merck Serono S.A., 2011
    • Table 53: Emerging Cancer Vaccines Market, Global, Pipeline Products, Amgen, 2011
    • Table 54: Emerging Cancer Vaccines Market, Global, Pipeline Products, GSK, 2011
    • Table 55: Emerging Cancer Vaccines Market, Global, Pipeline Products, Dendreon, 2011
    • Table 56: Emerging Cancer Vaccines Market, Global, Pipeline Products, KAEL-GemVax, 2011
    • Table 57: Emerging Cancer Vaccines Market, Global, M&A by Year, 2004-2011
    • Table 58: Emerging Cancer Vaccines Market, Global, M&A by Company, 2004-2011
    • Table 59: Emerging Cancer Vaccines Market, Global, Top 10 M&A by Value ($m), 2004-2011
    • Table 60: Emerging Cancer Vaccines Market, Global, Deals by Year, 2004-2011
    • Table 61: Emerging Cancer Vaccines Market, Global, Deals by Company, 2004-2011
    • Table 62: Emerging Cancer Vaccines Market, Global, Top 10 Licensing Deals by Value ($m), 2004-2011
    • Table 63: Emerging Cancer Vaccines Market, Global, Co-Developments by Year, 2004-2011
    • Table 64: Emerging Cancer Vaccines Market, Global, Top Five Co-Developments by Value ($m), 2004-2011
  • 1.2 List of Figures
    • Figure 1: Emerging Cancer Vaccines Market, Global, Revenue Forecasts ($m), 2006-2017
    • Figure 2: Emerging Cancer Vaccines Market, Global, Annual Cost of Vaccination ($), 2006-2017
    • Figure 3: Emerging Cancer Vaccines Market, Global, Target and Coverage Population ('000), 2006-2017
    • Figure 4: Cervical Cancer Vaccines Market, Global, Revenue Forecasts ($m), 2006-2017
    • Figure 5: Cervical Cancer Vaccines Market, Global, Annual Cost of Vaccination ($), 2006-2017
    • Figure 6: Cervical Cancer Vaccines Market, Global, Target and Coverage Population ('000), 2006-2017
    • Figure 7: Cervical Cancer Vaccines Market, Geographical Segmentation, Revenue Forecasts ($m), 2006-2017
    • Figure 8: Prostate Cancer Vaccines Market, Global, Revenue Forecasts ($m), 2010-2017
    • Figure 9: Prostate Cancer Vaccines Market, Global, Annual Cost of Vaccination ($), 2010-2017
    • Figure 10: Prostate Cancer Vaccines Market, Global, Target and Coverage Population ('000), 2010-2017
    • Figure 11: Prostate Cancer Vaccines Market, Geographical Segmentation, Revenue Forecasts ($m), 2010-2017
    • Figure 12: Lung Cancer Vaccines Market, Global, Revenue Forecasts ($m), 2010-2017
    • Figure 13: Lung Cancer Vaccines Market, Global, Annual Cost of Vaccination ($), 2010-2017
    • Figure 14: Lung Cancer Vaccines Market, Global, Target and Coverage Population ('000), 2010-2017
    • Figure 15: Lung Cancer Vaccines Market, Geographical Segmentation, Revenue Forecasts ($m), 2010-2017
    • Figure 16: Pancreatic Cancer Vaccines Market, Global, Revenue Forecasts ($m), 2010-2017
    • Figure 17: Pancreatic Cancer Vaccines Market, Global, Annual Cost of Vaccination ($), 2010-2017
    • Figure 18: Pancreatic Cancer Vaccines Market, Global, Target and Coverage Population ('000), 2010-2017
    • Figure 19: Pancreatic Cancer Vaccines Market, Global, Geographical Segmentation, Revenue Forecasts ($m), 2010-2017
    • Figure 20: Melanoma Vaccines Market, Global, Revenue Forecasts ($m), 2010-2017
    • Figure 21: Melanoma Vaccines Market, Global, Annual Cost of Vaccination ($), 2010-2017
    • Figure 22: Melanoma Cancer Vaccines Market, Global, Target and Coverage Population ('000), 2010-2017
    • Figure 23: Melanoma Vaccines Market, Global, Geographical Segmentation, Revenue Forecasts ($m), 2010-2017
    • Figure 24: Emerging Cancer Vaccines Market, The US, Revenue Forecasts ($m), 2006-2017
    • Figure 25: Emerging Cancer Vaccines Market, The US, Annual Cost of Vaccination ($), 2006-2017
    • Figure 26: Emerging Cancer Vaccines Market, The US, Target and Coverage Population ('000), 2006-2017
    • Figure 27: Emerging Cancer Vaccines Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2010-2017
    • Figure 28: Emerging Cancer Vaccines Market, Top Five Countries of Europe, Annual Cost of Vaccination ($), 2006-2017
    • Figure 29: Emerging Cancer Vaccines Market, Top Five Countries of Europe, Target and Coverage Population ('000), 2006-2017
    • Figure 30: Emerging Cancer Vaccines Market, Japan, Revenue Forecasts ($m), 2010-2017
    • Figure 31: Emerging Cancer Vaccines Market, Japan, Annual Cost of Vaccination ($), 2010-2017
    • Figure 32: Emerging Cancer Vaccines Market, Japan, Target and Coverage Population ('000), 2010-2017
    • Figure 33: Emerging Cancer Vaccines Market, Global, R&D Pipeline by Phase (%), 2011
    • Figure 34: Emerging Cancer Vaccines Market, Global, R&D Pipeline by Indication (%), 2011
    • Figure 35: Prostate Cancer Vaccines Market, Global, R&D Pipeline (%), 2011
    • Figure 36: Lung Cancer Vaccines Market, Global, R&D Pipeline (%), 2011
    • Figure 37: Pancreatic Cancer Vaccines Market, Global, R&D Pipeline (%), 2011
    • Figure 38: Melanoma Vaccines Market, Global, R&D Pipeline (%), 2011
    • Figure 39: Cervical Cancer Vaccines Market, Global, R&D Pipeline (%), 2011
    • Figure 40: Emerging Cancer Vaccines Market, Global, Market Share Analysis by Company (%), 2010
    • Figure 41: Emerging Cancer Vaccines Market, Merck & Co., Inc, SWOT Analysis, 2011
    • Figure 42: Emerging Cancer Vaccines Market, Merck Serono, SWOT Analysis, 2011
    • Figure 43: Emerging Cancer Vaccines Market, Amgen, SWOT Analysis, 2011
    • Figure 44: Emerging Cancer Vaccines Market, GSK, SWOT Analysis, 2011
    • Figure 45: Emerging Cancer Vaccines Market, Dendreon, SWOT Analysis, 2011
    • Figure 46: Emerging Cancer Vaccines Market, Global, M&A by Year, 2004-2011
    • Figure 47: Emerging Cancer Vaccines Market, Global, M&A by Geography (%), 2004-2011
    • Figure 48: Emerging Cancer Vaccines Market, Global, M&A by Value ($m), 2004-2011
    • Figure 49: Emerging Cancer Vaccines Market, Global, M&A by Type (%), 2004-2011
    • Figure 50: Emerging Cancer Vaccines Market, Global, M&A by Company, 2004-2011
    • Figure 51: Emerging Cancer Vaccines Market, Global, Deals by Year, 2004-2011
    • Figure 52: Emerging Cancer Vaccines Market, Global, Deals by Geography (%), 2004-2011
    • Figure 53: Emerging Cancer Vaccines Market, Global, Deals by Value ($m), 2004-2011
    • Figure 54: Emerging Cancer Vaccines Market, Global, Deals by Company, 2004-2011
    • Figure 55: Emerging Cancer Vaccines Market, Global, Co-Developments by Year, 2004-2011
    • Figure 56: Emerging Cancer Vaccines Market, Global, Co-Developments by Geography (%), 2004-2011
    • Figure 57: Emerging Cancer Vaccines Market, Global, Co-Developments by Value ($m), 2004-2011
+44 20 8816 8548

Ask a question about Emerging Cancer Vaccines Market to 2017

Enter the characters you see in the picture below
Captcha